BioWorld Asia

Oct. 5, 2005

Scientists Probe Signature' Of Cancer Genetic Damage

NatImmune, Enzon Enter Deal On Recombinant MBL

Closing In On First Revenues, Phoqus Seeking IPO On Aim

MMI Raises £10M For Genvax's Clinical Studies Of Vaccines

Other News To Note

Karo Bio Seeking SEK280M In Discounted Rights Issue

Karo Bio AB is seeking SEK280 million (US$35.9 million) in a discounted rights issue to fund its switch from early stage discovery to clinical development. (BioWorld International) Read More

SkyePharma Raising Funds After Scuttled Partner Deal

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...